Sept 20 (Reuters) – Shanghai Shen Lian Biomedical Corp : * SAYS PHASE II CLINICAL TRIAL OF UB-221 FOR CHRONIC SPONTANEOUS URTICARIA TREATMENT MEETS PRIMARY ENDPOINT Source text Further company
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Nov 7 (OPTA) - Results and fixtures for the J-League on Saturday (start times are…
(Adds background in 2-3) BAGHDAD, Nov 7 (Reuters) - Iraq produces more than 5 million…
Nov 7 (OPTA) - Scoreboard at stumps on the first day of 3rd four-day match…
Nov 7 (OPTA) - Scoreboard at close of play of 2nd odi between New Zealand…
VIDEO SHOWS: HIGHLIGHTS OF OS ANGELES LAKERS V PORTLAND TRAIL BLAZERS REGULAR NBA SEASON GAME…